Conversion From Belatacept to Another Immunosuppressive Regimen in Maintenance Kidney-Transplantation Patients.
Fiche publication
Date publication
décembre 2020
Journal
Kidney international reports
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DUCLOUX Didier
Tous les auteurs :
Gouin A, Sberro-Soussan R, Courivaud C, Bertrand D, Del Bello A, Darres A, Ducloux D, Legendre C, Kamar N
Lien Pubmed
Résumé
During the coronavirus disease 2019 (Covid-19) pandemic, several physicians have questioned pursuing belatacept in kidney-transplant patients in order to reduce the risk of nosocomial transmission during the monthly infusion. The effect of the conversion from belatacept to another immunosuppressive regimen is underreported. The aim of the present retrospective study was to assess the effect on kidney function and the clinical outcome of the conversion from belatacept to another regimen.
Mots clés
belatacept, calcineurin inhibitor, conversion, donor-specific antibody, kidney function, safety
Référence
Kidney Int Rep. 2020 Dec;5(12):2195-2201